Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frontline Ruxolitinib With De-Intensified HLH-94 for Adult HLH
NCT06160791Phase 2Recruiting
- Start
- Oct 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in hemophagocytic lymphohistiocytosis (HLH). Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT06160791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06160791.